Suomen Terveystalo Oy
- Address
- Albertinkatu 16, 90100 Oulu, Finland
Diseases of the nervous system and mental disorders
At Suomen Terveystalo Oy in Oulu, several trials focus on Alzheimer’s disease, including mild to moderate Alzheimer’s disease and early Alzheimer’s disease. This research is centered on understanding whether new treatments can help preserve thinking skills and daily function, while also assessing overall safety and tolerability.
- Studying whether experimental therapies can improve cognition and global functioning in Alzheimer’s disease
- Evaluating treatment effectiveness in mild to moderate and early Alzheimer’s disease
- Assessing the safety and long-term tolerability of new approaches for cognitive impairment
The site’s work in this area reflects a strong interest in therapies that may slow decline and support better quality of life for people living with neurodegenerative disease.
Digestive system diseases
Clinical research here also includes celiac disease, with studies looking at ways to relieve symptoms in people who continue to experience problems despite following a gluten-free diet. The main goal is to test whether a new treatment can improve comfort and reduce ongoing disease burden.
- Focused on symptom improvement in celiac disease
- Exploring treatment options for people with persistent symptoms and mucosal damage
- Aiming to improve day-to-day disease control beyond standard dietary management
This area highlights research into better care for gastrointestinal disorders where current management may not fully resolve symptoms.
Nervous system diseases and headache disorders
Another major research focus at the site is migraine, including chronic migraine and preventive care for children and adolescents. These trials are designed to see whether new or existing therapies can reduce migraine frequency and improve long-term control in younger patients.
- Investigating prevention of migraine in pediatric and adolescent populations
- Comparing treatment effectiveness for chronic migraine
- Supporting better preventive options for people with recurring headache disorders
The migraine studies show a clear emphasis on improving prevention strategies for a condition that can significantly affect school, work, and everyday life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Suomen Terveystalo Oy
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of Subcutaneous Tertomotide (GV1001) in Mild to Moderate Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled Study | Gemvax & Kael Co. Ltd. | Phase II | Not Recruiting | Nov 2022 | Apr 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tertomotide | 1 | Unknown | 2022-11-08 | 2022-11-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.